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High-intensity focused ultrasound (HIFU) is a non-invasive method of
selective placental vascular occlusion, providing a potential therapy for con-
ditions such as twin–twin transfusion syndrome. In order to translate this
technique into human studies, evidence of prolonged fetal recovery andmain-
tenance of a healthy fetal physiology following exposure to HIFU is essential.
At 116+ 2 days gestation, 12 pregnant ewes were assigned to control (n ¼ 6)
or HIFU vascular occlusion (n ¼ 6) groups and anaesthetized. Placental blood
vessels were identified using colour Doppler ultrasound; HIFU-mediated
vascular occlusion was performed through intact maternal skin (1.66 MHz,
5 s duration, in situ ISPTA 1.8–3.9 kW cm
22). Unidentifiable colour Doppler
signals in targeted vessels followingHIFU exposure denoted successful occlu-
sion. Ewes and fetuses were then surgically instrumented with vascular
catheters and transonic flow probes and recovered from anaesthesia. A
custom-made wireless data acquisition system, which records continuous
maternal and fetal cardiovascular data, and daily blood sampling were used
to assess wellbeing for 20 days, followed by post-mortem examination.
Based on a comparison of pre- and post-treatment colour Doppler imaging,
100% (36/36) of placental vessels were occluded following HIFU, and occlu-
sion persisted for 20 days. All fetuses survived. No differences in maternal or
fetal blood pressure, heart rate, heart rate variability, metabolic status or oxy-
genation were observed between treatment groups. There was evidence of
normal fetal maturation and no evidence of chronic fetal stress. There were
no maternal injuries and no placental vascular haemorrhage. There was both
a uterine and fetal burn, which did not result in any obstetric or fetal compli-
cations. This study demonstrates normal long-term recovery of fetal sheep
from exposure to HIFU-mediated placental vascular occlusion and underlines
the potential of HIFU as a potential non-invasive therapy in human pregnancy.1. Introduction
There has been increasing interest in the use of high-intensity focused ultrasound
(HIFU) in fetal medicine since it has the potential to target fetal tissue and blood
vessels within the amniotic cavity, and placental blood vessels without requiring
highly intrusive access to the uterus. A number of applications have been
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2suggested, including the treatment of broncho-pulmonary
sequestration and sacrococcygeal teratoma [1]. Recently,
HIFU has been used to ablate the soft tissue of the umbilical
cord insertion point in the acardiac twin, using both B-mode
and colour Doppler ultrasound imaging for targeting, in preg-
nancies complicated by twin reversed arterial perfusion
sequence with a 50% efficacy rate [2,3].
Ultrasound-guided HIFU has also been proposed as a
method of selective vascular occlusion [1], potentially provid-
ing a non-invasive treatment for conditions such as twin–twin
transfusion syndrome (TTTS), which arise from abnormal pla-
cental vascular anastomoses [4,5]. This addresses an important
unmet clinical need, as TTTS remains the leading cause of
death, disability and premature delivery in twins, and inva-
sive therapies such as selective fetoscopic laser ablation of
placental anastomoses offer no survival advantage to affected
fetuses compared to amniodrainage [6]. This is probably due
more to the invasive nature of fetoscopic techniques, which
require entry into the intrauterine space (hence disrupting
the amniotic sac), than to the occlusion of the abnormal pla-
cental vascular connections which cause the condition. HIFU
offers a non-invasive alternative to such techniques. HIFU-
mediated ablation of in utero soft tissue, including placental
tissue, has been demonstrated in human and animal studies
[2,4,7–9]. Our group has demonstrated selective placental vas-
cular occlusion in animal studies, both transuterine and
through intact maternal skin [5,10]. While providing evidence
of feasibility, these studies did not constitute sufficient ‘proof
of principle’ to translate our techniques into human studies.
In our earlier transuterine study, the protocol did not seek to
demonstrate fetal survival beyond 30 min from the end of
exposure to HIFU in sheep pregnancy. Prior to translation
into human therapy, evidence of prolonged fetal recovery,
as well as the long-term maintenance of a healthy fetal
physiological state following HIFU treatment, is essential [5].
Our second study using pregnant sheep demonstrated
that it is possible to use ultrasound-guided HIFU to occlude
placental vasculature selectively through intact maternal skin,
although 50% of subjects experienced a skin burn, and a
further 33% experienced skin erythema. This raises the
additional question of whether sufficient HIFU energy
could be delivered to the intrauterine space through maternal
intact skin without incurring skin damage [10], prior to
translation to human clinical therapy.
We have now developed a wireless data acquisition system
(CamDAS: Cambridge Data Acquisition System) that permits
maternal and fetal cardiovasculardata tobe recordedcontinually
from the end of surgical instrumentation, through recovery from
anaesthesia and longitudinally until the end of the experiment in
free-moving animals [11]. Therefore, the primary aim of this cur-
rent studywas to establish fetal andmaternal cardiovascular and
metabolic long-term recoveryusingCamDAS in sheep following
ultrasound-guidedHIFUapplied through intactmaternal skin to
occlude placental blood vessels selectively. The secondary aim
was to determine the rates of successful vascular occlusion and
associated iatrogenic harm when lower ultrasound energy
levels were delivered to the target blood vessels.2. Material and methods
All procedures were performed in accordance with the UK Ani-
mals (Scientific Procedures) Act 1986 and were approved by the
Ethical Review Committee of the University of Cambridge.Twelve singleton Welsh mountain sheep fetuses at 116+2 d
gestational age (median+ range, term approx. 147 days) were
used. Six ewes were exposed to HIFU and six animals were
not, forming the control group.
2.1. Induction and maintenance of general anaesthesia
Animals were fasted, with free access to water, for 24 h before the
induction of anaesthesia. The maternal abdomen was shaved
24–48 h prior to the experimental procedures. On the day of
exposure to HIFU or sham (day 0), general anaesthesia was
induced with alfaxalone 3 mg kg21 (IV, Alfaxan, Jurox) and
maintained with isoflurane (inhaled, 1.5–2.5% in 4 : 1 O2:N2O).
Ewes were mechanically ventilated and maternal oxygen satur-
ation and end-tidal carbon dioxide (EtCO2) were monitored
non-invasively; maternal SpO2 was maintained greater than
94% and EtCO2 was maintained at less than 6%.
2.2. Preparation of maternal abdominal skin and
establishment of an acoustic window
Following induction of anaesthesia, maternal abdominal skin
was washed with iodine scrub solution (Vetasept: 7.5% povidone
iodine, Animalcare Ltd) to remove dirt and lanolin and washed
again with plain water. If proceeding to HIFU exposures, remain-
ing hair was chemically depilated (Nairw hair removal cream,
Church & Dwight Co.), the skin was washed with plain water,
then wetted with degassed water. A ‘water bag’ made from poly-
thene was placed in contact with the maternal abdomen, filled
with degassed water and suspended from a fixed support.
Trapped air between the plastic and the skin was removed by
smoothing the plastic against the skin, until no remaining air
pockets were identified visually. The water in the bag was con-
tinuously cooled to 20.5–25.78C and degassed to 1.9–3.0 mg l21
dissolved oxygen throughout the duration of the HIFU protocol.
2.3. High-intensity focused ultrasound protocol
Following anaesthesia and skin preparation, but prior to any
invasive surgical procedures, HIFU was applied through intact
maternal skin. The HIFU transducer (Sonic Concepts H148MR
transducer, frequency 1.66 MHz, 64 mm diameter, 63 mm focal
length, 19 mm central aperture for ultrasound imaging, focal
spot diameter 1.2 mm, axial focal spot length 8.9 mm) was sup-
ported in its position within the water bag using a gantry arm
with three-dimensional automated positioning (able to move
on X-, Y- and Z-axes). Manual angulation of the transducer
was possible before the start of an exposure series, but not
during one (electronic supplementary material, figure S2). A
signal generator fed a power amplifier (A330, E&I Ltd, Rochester,
NY) which was used to control the transducer output. A graphi-
cal user interface (Matlab R2013a, Mathworks) on a laptop
computer was used to control and log (i) the automated gantry
position, (ii) signal generator settings and (iii) timing of
exposures. B-mode and colour Doppler imaging were used to
identify target vessels (4–10 MHz sector phased array diagnostic
ultrasound transducer, P10–4, Z.one Zonare, Mindray, China).
The diagnostic transducer was centrally mounted behind the
HIFU transducer in a fixed position and provided imaging
through the central aperture. The target vessels were chosen
to be within 1–4 cm below the skin and able to be imaged
satisfactorily by colour Doppler. There were six target vessels
in each animal in the HIFU-exposed group, and none in the
control animals.
Four to seven HIFU exposures of 5 s duration, spaced 5 s and
2 mm apart, were applied. This separation was chosen to give a
contiguous lesion, in the form of a single linear track, placed
across the vessel. The number of exposures was selected based
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3on the length of this track, which was required to start and end in
placental tissue. The acoustic power used was designed to deliver
approximately 2.5–3.0 kW cm22 estimated in situ intensity to the
target vessel at different focal depths beneath the maternal skin:
greater than or equal to 30.0 mm ¼ 78 W; 25.0–29.9 mm¼ 62 W;
20.0–24.9 mm¼ 50 W; less than or equal to 14.9 mm¼
40 W. Estimated in situ intensity was calculated based on the
attenuation coefficients of the overlying animal tissues, deter-
mined in a previous study [12]. The safety precautions used
were that: (i) movement of the mechanical gantry arms was
restricted to a single direction along an axis at 908 to the direction
of sound/vertical midline of the ultrasound image and (ii) HIFU
exposure series were not planned or delivered in vascular targets
in which fetal parts could be seen in the post-focal region.
Target vessels were assessed before, and immediately after,
HIFU exposure using colour Doppler in the same three-dimen-
sional position (determined using the automated gantry), with
3 s video clips being recorded. Treatment success was defined
as no flow being detectable on colour Doppler after treatment
using the lowest velocity scale setting (26.3 to 6.3 cm s21), and
the highest gain setting that did not cause colour saturation. In
the event of a failed occlusion, one further HIFU exposure
track per target vessel was allowed, unless the maternal injury
was suspected after the first track. The maternal skin was
inspected for evidence of skin changes and photographed
before and after the completion of each series of HIFU exposures.
Superficial skin reddening which blanched with pressure
and which resolved fully at any time within 24 h was described
as erythema; more severe thermal skin injuries were described as
a skin burn.
2.4. Maternal and fetal surgery
Following the completion of HIFU exposures, or, for the control
group following the induction of anaesthesia, surgery was com-
menced under aseptic conditions as described previously [5]. In
brief, a midline incision was made in the maternal abdomen to
access the pregnant uterus. The rectus sheath, omentum and ser-
osal surface of the uterus were visually examined for evidence of
thermal injury. A hysterotomy was performed in the uterus and
the fetal hindlimbs were exteriorized, with care taken to preserve
amniotic fluid. On one side, the femoral artery was cannulated
with an arterial catheter. On the contralateral side, a 2 mm aper-
ture time-transit time flow probe (R series, Transonic Systems
Inc., Ithaca, USA) was placed around the femoral artery.
A third catheter was secured to the fetal hind limb for the moni-
toring of the amniotic cavity pressure. The maternal left femoral
artery and vein were also cannulated. Incisions in the fetal skin,
uterus, rectus sheath and maternal abdominal skin were closed.
Vascular catheters were exteriorized via a keyhole incision on
the maternal flank; flow probe cables were exteriorized through
the contralateral flank.
Antibiotics were given following uterine closure (600 mg
benzylpenicillin IA, Crystapen, Genus Pharmaceuticals, Newbury,
UK). Inhalational anaesthesia was withdrawn and the animal
was extubated when the spontaneous respiratory effort was
re-established.
2.5. Post-operative care
Ewes were housed in individual floor pens with a 12 L : 12 D
cycle with ad libitum access to hay, nuts and water. Maternal anti-
biotics (procaine benzylpenicillin 15 mg kg21 IM, Depocillinw,
Intervet UK Ltd, Milton Keynes, UK) were administered for 5
days following surgery and fetal antibiotics (600 mg benzylpeni-
cillin IA, Crystapen, Genus Pharmaceuticals, Newbury, UK)
were administered daily until the end of the experiment.
Maternal analgesia (carprofen 1.4 mg kg21 SC, Rimadyl
TM
, Pfizer
Ltd, Sandwich, UK) was administered for three post-operativedays, and as required if signs of maternal pain were evident
based on behaviour, facial expressions, stance and feeding pat-
terns. Animals were checked daily for signs of maternal pain
and distress, problems with mobility, bladder or bowel function,
preterm labour or rupture of membranes or vaginal bleeding.2.6. Assessment of materno-fetal cardiovascular status
during recovery
Intra-arterial catheters were connected to pressure transducers
(ArgoTrans
TM
Transducer, Argon Medical Devices Inc., Plano,
TX,USA) positioned at the level of thematernal heart. Phasic arter-
ial pressure recordings were corrected for atmospheric pressure
(maternal) or amniotic cavity pressure (fetal). Pressure transducers
and time-transit transducers were connected to a customized data
acquisition system, the CamDAS [11,13]. This is an ambulatory
system, housed in a protective jacket worn by the pregnant ewe.
It samples (at 500 KHz) and continuously transmits digitized arter-
ial blood pressure and arterial flow information to a laptop
running IDEEQ (Maastricht Instruments, Maastricht, Nether-
lands). Recorded datawere available thereafter for offline analysis.
Data were consolidated into files containing 24 h (00:00:00 to
23:25:59) and uploaded into a data analysis program (Labchart 7
Pro, AD Instruments Ltd, New Zealand). Mean values for
sequential 1-min epochs (minute means) were generated for the
systolic peak, diastolic nadir and amplitude of maternal and
fetal arterial blood pressures. Minute means for mean arterial
flow rate and mean amniotic cavity pressure were also generated
by this method. Minute means for each parameter were exported
to a customized spreadsheet (Excelw, Microsoft Corporation,
Redmond, WA, USA) and logic checked for artefactual data
which were non-physiological and produced due to catheter
blockage or equipment error, which was excluded. From the
remaining data, minute mean values within any given hour
were then averaged to give hourly means, and hourly means
were further averaged to give the daily means reported here
(electronic supplementary material, figure S1). This method of
using time epochs and sequential averaging is recognized to pre-
vent time periods with greater periods of excluded ‘artefact data’
being under-represented in the overall average [14].2.7. Assessment of materno-fetal metabolic status
during recovery
Blood samples taken from the maternal and fetal descending
aortic catheters (0.3 ml each) were drawn into sterile syringes
on a daily basis (electronic supplementary material, figure S1).
These were used to determine pH, arterial base excess (ABE),
concentration of bicarbonate, partial pressures of oxygen and
carbon dioxide (ABL5 Blood Gas Analyser, Radiometer, Copen-
hagen, Denmark). Blood glucose and lactate concentrations
were obtained from an automated analyser (YSI 2300 Stat Plus,
Yellow Springs Instruments, Ohio, USA). In the HIFU-exposed
animals, haemoglobin and oxygen saturation of the blood were
determined using an ABL80 Flex analyser (Radiometer, Copen-
hagen, Denmark). In control animals, the haemoglobin and
oxygen saturation of blood were determined using an OSM3 ana-
lyser (Radiometer, Copenhagen, Denmark), due to a change of
laboratory equipment during the duration of the experiments.
Results obtained by these two methods have been previously
compared internally at time of machine replacement and are
highly comparable (private communication). Values for haema-
tocrit were obtained in duplicate using a microhaematocrit
centrifuge (Hawksley, Lancing, UK).
On the fifth day post-HIFU (baseline) and the day of post-
mortem (day 20, electronic supplementary material, figure S1),
a further 5 ml of maternal and fetal blood was collected into
estimated in situ intensity (kW cm–2)
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Figure 1. De-escalation of estimated in situ intensities resulting in successful
occlusion. The curves show the distribution of relative frequencies of estimated
in situ intensities resulting in successful occlusion in this animal group (solid
line), the previous transabdominal animal group (dashed line (9)), and the
transuterine animal group (dotted line (4)). In this animal group, the
median estimated in situ intensity required to produce occlusion was
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4EDTA and centrifuged (5000 rpm, 48C, 5 min) for plasma extrac-
tion. All samples were then frozen at 2808C for later analysis.
The concentration of fetal cortisol in plasma was quantified
using a commercially available cortisol indirect enzyme-linked
immunosorbent assay kit (RE52061, IBL International, Hamburg,
Germany), as described in detail recently [15]. In brief, duplicate
20 ml plasma aliquots (undiluted, previously unthawed) were
tested according to the product instructions. The optical density
of the wells was read (wavelength 450 nm, ELx800 Absorbance
Reader, Biotek, Winooski, VT, USA) within 10 min of the
end of the assay. A standard curve for interpretation of the
results of each plate was produced by plotting the mean optical
density of manufacturer-provided standard concentrations of
cortisol against their known concentrations. The equation of the
resulting line of best fit was used to extrapolate cortisol concen-
trations from measured optical densities of fetal samples. The
inter-assay coefficient of variation (CV) was 5.1%; the intra-
assay CV was 4.8%.2.6 kW cm22 (IQR 2.5–2.9, range 1.8–3.9). In the previous transabdominal
group, it was 2.9 kW cm22 (IQR 2.5–3.1, range 2.3–4.4) and in the transu-
terine group, it was 5.4 kW cm22 (IQR 5.0–5.5, range 3.9–5.6). This
represents a deliberate de-escalation of in situ intensities delivered in recog-
nition that the targets in the transuterine animal group were exposed to
in situ intensities in excess of what was required to produce vascular occlusion.
terface
16:201900132.8. Assessment of fetal heart rate variability during
recovery
The fetal heart rate was sampled daily in six, 5-min blocks spaced
evenly between 00.00 and 06.00 using the waveform derived
from fetal descending aorta catheter signals, from the first post-
operative day to the day of the post-mortem examination,
using a method previously described by our group [15]. Blocks
were visually identified as quiet sleep or active sleep. Time
domain and power spectral analysis were then performed in Lab-
chart; based on the previously published literature, the frequency
boundaries used were: very low frequency 0–0.04 Hz, low fre-
quency (LF) 0.04–0.15 Hz, high frequency (HF) 0.15–0.4 Hz
[16–18]. Mean daily values for the standard deviation of
normal to normal R–R intervals (SDNN), root mean square of
the successive differences, absolute and normalized LF and HF,
LF/HF ratio and total power were calculated daily from the
5-min samples. Short-term variation (STV) was calculated
using R–R intervals generated by Labchart in a customized
Excel spreadsheet, as previously published [19].2.9. Post-mortem examination
On ‘day 20’, the ewe and fetus were euthanized for post-mortem
examination and tissue collection under schedule one of the UK
Animals (Scientific Procedures) Act 1986. A slow IV injection into
the maternal jugular vein of 120 mg kg21 pentobarbitone sodium
(Pentojectw, Animalcare Ltd, York, UK) was used for this
purpose. A systematic visual inspection of (i) maternal skin,
(ii) maternal rectus sheath, (iii) anterior and posterior surface of
the uterus, (iv) fetal skin (dorsal, ventral, left and right lateral
views) and (iv) maternal bladder and bowel was performed.
Fetuses were weighed and measured. All placentomes were
excised, bisected and examined for evidence of tissue damage,
in both exposed and control animals. Placentomes with evidence
of tissue damage were retained for histological examination. Col-
lected tissues were immersion fixed in 10% neutral buffered
formalin for 5 days before embedding in paraffin wax. Eight
micrometre sections were stained with haematoxylin and eosin
(H&E) to provide a detailed view of damaged and undamaged
tissues, and with phosphotungstic acid–haematoxylin (PTAH)
stains to identify areas of fibrin deposition. Measurements
taken from histological sections were not corrected for shrinkage,
as it was not known whether shrinkage rates of damaged and
undamaged tissue were comparable. Measurements therefore
represent a minimum size, which may have been reduced
artificially by fixation.2.10. Statistical analyses
The study was powered to detect a difference in means of greater
than or equal to 2.5 at a ¼ 0.05 with a power of 80%, based on the
published data of response to an acute insult (hypoxia or hypo-
tension) in chronically instrumented sheep fetuses.
All statistical analysis was performed in SPSS (v. 22, IBM,
NY, USA). Graphs were drawn in GraphPad Prism (v. 6, Graph-
Pad Software, Inc., San Diego, CA, USA). Statistical significance was
accepted when p, 0.05 for all tests, although where applicable
individual p-values are presented in graphs, tables and text.
Continuous data were assessed for normality using the
Shapiro–Wilk test. Descriptive analysis was performed using
mean+ standard error of the mean (s.e.m.), unless otherwise
stated. A two-tailed Student’s t-test was used to compare
means (normally distributed) or a Mann–Whitney U-test was
used to compare medians (non-parametric data).
To assess the effect of HIFU treatment on a continuous
dependent variable when additional independent variables
needed to be considered, two-way ANOVA testing was used.
A repeated measures two-way ANOVA was used to investigate
the change in the dependent categorical variable due to the
interaction of gestational age/time with HIFU treatment. If a sig-
nificant effect or interaction was identified, post hoc testing was
performed as applicable to identify the source of variation.
Values were compared to a baseline set on day 5 post-operative.
This was done as standard experimental practice is to allow 4
days post-operative recovery in the pregnant sheep model and
perform baseline recordings on day 5.3. Results
3.1. Efficacy of vascular occlusion
Based on the comparison of pre- and post-HIFU exposure
colour Doppler imaging, 36 of 36 target placental blood
vessels were successfully occluded. Regarding successful
occlusions, 33 of 36 vessels were occluded following the initial
HIFU exposure series. In the remaining three vessels, target-
ing errors of between 5 and 10 mm were identified during
the experimental protocol. Once these errors had been
(a)
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1 mm
(c)
(d )(b)
Figure 2. Macroscopic tissue damage and histological confirmation of vascular occlusion after 21 days. (a) The photograph shows a placentome bisected 21 days
after exposure to HIFU, photographed after formalin fixation for 24 h, with areas of tissue pallor surrounded by an area of tissue darkening. (b) The line diagrams of
the photograph in (a) represent (i) tissue pallor, (ii) tissue darkening, (iii) placental vessels, (iv) area of materno-fetal exchange surrounding the origin of placental
vessels, (v) placentome soft tissue. (c) PTAH stain of fetal vessels in an unexposed placentome. The lumen is open and unobstructed and the connective tissue
around the vessels has regular purple staining of normal collagen. (d ) PTAH stain of a fetal vessel exposed to HIFU and thought to be occluded by colour flow
Doppler studies. The lumen is stained black, indicating that it is occluded by organized fibrin, a definitive appearance of the occlusive clot. Surrounding the vessels
there are regions of irregular, pale staining in the collagenous regions suggestive of vacuolar degeneration. (Online version in colour.)
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5corrected, these remaining three vessels were successfully
occluded. The median estimated in situ intensity which
resulted in successful occlusion was 2.6 kW cm22 (interquar-
tile range 2.5–2.9 kW cm22, range 1.8–3.9 kW cm22). The
distribution of estimated in situ intensities which resulted in
successful occlusion is shown in figure 1, which also presents
the equivalent data from our previous transdermal and trans-
uterine studies for comparison [5,10]. The mean depth of the
target vessels was 24 mm (s.d.+6 mm) beneath the maternal
abdominal skin surface.
At post-mortem examination, 21 days following exposure
to HIFU, six placentomes with macroscopic evidence of HIFU
tissue damage were recovered from each animal in the
HIFU-exposed group (a total of 36, figure 2a). There was no
evidence of haemorrhage of placental vessels, nor damage
to the fetal membranes, at the time of post-mortem examin-
ation (blood or clots in the allantoic membranes). No
macroscopic tissue damage was seen in any of the placen-
tomes of the control animals.
Trapped erythrocytes within the vessel lumen, suggestive
of the occlusive clot, were found in 36/36 placentomes, which
had been exposed to HIFU under histological examination
using H&E staining. PTAH staining confirmed the presence
of organized fibrin in those vessels in which trapped erythro-
cytes were seen (figure 2b). Vacuolar change, suggestive of
degeneration of the connective tissue surrounding vessels,
was found surrounding occluded vessels in 27/36 placen-
tomes (figure 2c). The mean diameter of occluded vessels
was 1.4 mm (range 0.3–4.1 mm, without correction for
tissue shrinkage).3.2. Fetal survival and growth
All the fetuses survived, undelivered, to the end of the 21-day
follow-up period. Fetal weight at post-mortem examination
was 3.3+0.2 kg in the control group, and 3.4+0.1 kg in the
HIFU-exposed group (p ¼ 0.58). Fetal body mass index was17.3+0.8 kg m22 in control fetuses and 16.4+0.7 kg m22 in
those HIFU-exposed (p ¼ 0.46). Both control and HIFU-
exposed fetuses showed appropriate symmetric growth, as
the ratio of bi-parietal diameter to abdominal circumference
was normal and similar between groups 0.18+0.01 (control)
and 0.21+0.01 (HIFU, p ¼ 0.06).
3.3. Fetal cardiovascular recovery
Following 5 days of post-operative recovery, fetal heart rate,
fetal mean arterial blood pressure, fetal femoral arterial
blood flow and fetal femoral arterial vascular resistance
were the same between HIFU-exposed and control groups.
Fetal femoral vascular resistance was elevated in the first
24 h following surgery and gradually recovered to basal
levels by the fourth post-operative day, without evidence of
an additive effect of HIFU exposure. In all fetuses, there
was an ontogenic increase in arterial blood pressure and
femoral blood flow and a fall in fetal heart rate with advan-
cing gestation. These maturational effects of advancing
gestational age on fetal cardiovascular function were not
affected by HIFU exposure (figure 3).
3.4. Fetal metabolic recovery
Immediately following the reversal of anaesthesia (day 0,
table 1), fetuses in both groups showed evidence of a partially
buffered mixed respiratory and metabolic acidosis, due to the
elevated arterial partial pressure of carbon dioxide (PaCO2)
and arterial lactate concentration. In the fetuses exposed to
HIFU, the ABE was reduced compared to baseline, while
the arterial bicarbonate concentration (HCO23 ) remained
unchanged compared to baseline. In the control fetuses,
ABE was elevated compared to the baseline, and HCO23
remained normal. The ABE and HCO23 were significantly
different between treatment groups.
By the first post-operative day, PaCO2 and arterial lactate
concentration had normalized compared to baseline in both
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Figure 3. Fetal mean arterial pressure, heart rate, femoral arterial blood flow and vascular resistance. Values represent the mean+ s.e.m. of fetal mean arterial
blood pressure, heart rate, fetal femoral arterial blood flow and vascular resistance averaged over sequential 24 h periods in HIFU-exposed (filled circles; n ¼ 6) or
control (open circles; n ¼ 6) animals. The dashed line represents the day 5 baseline against which other values were compared. Statistical significance was assessed
using a repeated measures two-way ANOVA with post hoc Tukey’s test; * denotes a significant difference of time with respect to baseline, with exact p-values given
on the graphs. There was no significant effect of treatment.
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6treatment groups and remained normal throughout the dur-
ation of the follow-up period. The ABE and HCO23 had also
normalized when compared to baseline by the first post-
operative day, although the difference between groups due
to the effect of treatment persisted until the third post-operat-
ive day, with the HIFU-exposed group having a lower ABE
and HCO23 than the control group fetuses.
At every point measured, fetal oxygenation remained
normal, in terms of both oxyhaemoglobin saturation and
arterial partial pressure of oxygen (PaO2), including immedi-
ately following the reversal of anaesthesia, when the fetuses
were mildly acidotic (day 0, table 1). There was a transient
elevation in fetal oxyhaemoglobin saturation on the first
post-operative day, with no change in PaO2. There was an
increase in femoral arterial oxygen delivery with increasing
gestational age, with no difference between treatment
groups noted.
Fetal haemoglobin and haematocrit were elevated
immediately following the reversal of anaesthesia and on
the first post-operative day (day 0–1, table 1). After this,
both normalized and remained stable compared to the day
5 baseline, with no evidence of fetal anaemia or effect of
gestational age or treatment noted.
The concentration of fetal arterial glucose and femoral
arterial glucose delivery following reversal of anaesthesia
(day 0, table 1) were normal when compared to baseline
(day 5) and were stable throughout the follow-up period.
There was no effect of gestational age or treatment group
observed.3.5. Fetal cortisol levels
Fetal plasma cortisol concentrations measured under basal
conditions were not different between treatment groups at
either of the two time points at which they were measured,
day 5 and day 20 post-operative (figure 4). At baseline (day
5), the fetal cortisol concentrations were low; however, there
was a gestational age-dependent increase in plasma cortisolconcentrations between day 5 and day 20, with no effect of
HIFU treatment.
3.6. Fetal heart rate variability
STV, SDNN and normalized low frequency (nLF) power in
active sleep were all elevated during the first three post-
operative days when compared to the day 5 baseline and
had normalized by the fourth post-operative day. Normalized
high frequency (nHF) power was not different compared to
baseline in the first four post-operative days. The ratio of
LF to HF power (LF/HF ratio) was elevated for the first
two post-operative days in both active and quiet sleep and
had normalized by the third post-operative day compared
to day 5 of baseline. These effects were seen in both the
HIFU-exposed and control fetuses, with no effect of treatment
group observed. There were also gestational age-dependent
increases in STV, SDNN, nLF and nHF power in active
sleep. The rate and degree of these increases were not affected
by treatment. There was no change in the ratio of LF to HF
(LF/HF ratio) power in either quiet or active sleep states
related to gestational age (figure 5).
3.7. Maternal cardiovascular recovery
Maternal heart rate and mean arterial blood pressure were not
altered from baseline, either in the immediate post-operative
period or at any point during the 21-day follow-up period.
No effect of treatment was observed (figure 6).
3.8. Maternal metabolic recovery
MaternalPaO2, oxyhaemoglobin saturation andarterial glucose
concentration were normal following the reversal of anaesthe-
sia and remained stable in the immediate post-operative
period and for the duration of the follow-up period.
However, immediately following the reversal of anaesthe-
sia (day 0, table 2), mothers in the control group showed
evidence of a respiratory acidosis, which was fully resolved
by the first post-operative day. Their pH was lowered
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Figure 4. Fetal plasma cortisol levels. Values represent mean+ s.e.m. of
fetal plasma cortisol concentrations 5 and 20 days after surgery in HIFU-
exposed (black bar, n ¼ 6) or control (open bar, n ¼ 6) fetuses. Significant
differences: *p, 0.001 effect of gestational age, two-way repeated
measures ANOVA with Tukey’s and Sidak’s post hoc tests. There was no
effect of treatment.
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8secondary to a raised PaCO2, and to a lesser degree, a raised
arterial lactate concentration.. There was evidence of partial
compensation of this acidosis, with a raised ABE and raised
arterial bicarbonate concentration. In the HIFU-exposed
mothers, the pH was not different to baseline; however, the
arterial bases excess and arterial bicarbonate were both
raised, suggesting a fully compensated respiratory acidosis.
In support of this, PaCO2 was raised by clinical standards
compared to baseline, but this change did not achieve statisti-
cal significance. These values had normalized by the first
post-operative day. There was a significant difference in
both pH and PaCO2 between control and HIFU-exposed ani-
mals, with control animals showing a greater respiratory
acidosis. The arterial lactate concentration was also raised
in these animals compared to baseline, with no difference
between treatment groups. While statistically significant, the
magnitude of this elevation of arterial lactate was not of clini-
cal consequence and was fully restored to baseline by the
second post-operative day. Thereafter, maternal pH, PaCO2,
ABE, arterial bicarbonate and lactate concentrations remained
stable for the duration of the follow-up period.
In both treatment groups, the mothers were haemodiluted
by the intraoperative crystalloid infusions following reversal
of anaesthesia, leading to an apparent fall in haemoglobin,
which had self-corrected by the first post-operative day.
Maternal haemoglobin and haematocrit remained stable fol-
lowing this and for the duration of the follow-up period
(table 2).
Maternal pH, PaCO2, PaO2, haemoglobin and arterial
glucose concentration remained stable in the immediate
post-operative period and for the duration of the follow-up
period. There was a transient elevation of arterial lactate in
both groups, which had resolved by the second post-operative
day (table 2).3.9. Maternal and fetal iatrogenic harm
There were no maternal skin burns as a result of the HIFU
exposure series performed. In one sheep, erythema of the
maternal abdominal skin was noted. In this animal,
six HIFU exposure series were performed, and in five of six
HIFU exposure series, maternal skin erythema resulted(figure 7a). These areas of skin redness were fully resolved
by the time of anaesthetic reversal. The five HIFU exposure
series in this animal which caused the skin erythema each
delivered six HIFU exposures, 2 mm apart, with an estimated
in situ intensity of 2.5–2.6 kW cm22, to vascular targets
17–32 mm beneath the maternal skin. There was only one
HIFU exposure series delivered to each target (which were
all successfully occluded). No errors in targeting the blood
vessels or operation of the HIFU system were identified.
The sixth HIFU exposure series, which did not result in
erythema, delivered seven exposures of 2.5 kW cm22 at a
target depth of 26 mm (electronic supplementary material,
table S1). As such, there was no clear difference between
the five exposure series that caused erythema and the one
that did not, nor was there an obvious cause for the
erythema based on operator or technical error. No maternal
veterinary skin abnormality was noted, and there was no
deviation from the standard method used for the prep-
aration of the skin in this animal relative to the other ewes
in this study. The maternal weight was 54 kg. There was
no maternal skin erythema observed in the other five
sheep exposed to HIFU.
There was a single instance of damage to the uterine
serosa noted at the time of laparotomy (day 0). This area
was not excised or repaired and had healed by the time of
post-mortem examination (day 20). There was no evidence
of uterine perforation or leakage of amniotic fluid resulting
from this injury (figure 7b,c). It was not possible to determine
which HIFU exposure series resulted in this uterine burn.
The HIFU exposure series delivered in this animal, one of
which caused the burn, were comprised of five to six
exposures, delivering an estimated in situ intensity of 2.0–
3.1 kW cm22, to vascular targets 19–28 mm beneath the
surface of the maternal skin. Only a single HIFU exposure
series was delivered to each vascular target (all of which
were occluded) and no errors in the operation of the HIFU
system or in the targeting of the blood vessel were identified
(electronic supplementary material, table S1). There were no
maternal skin burns, erythema or fetal injury noted in this
sheep. The maternal weight was 55 kg. Again, there was no
obvious cause for the uterine burn.
There was a single instance of a burn to a fetal hind limb,
which was first noted at the time of surgery during insertion
of fetal catheters (day 0). This was a direct result of a target-
ing error and resulted in the failure of vascular occlusion,
requiring the vessel to be retreated. The first (mistargeted)
HIFU exposure series delivered five HIFU exposures of
2.4 kW cm22 estimated in situ intensity to a depth of 20 mm
beneath the maternal skin. The fetal hind limb was 29 mm
beneath the surface of the skin and 9 mm beneath the vascu-
lar target, measured parallel to the direction of the sound.
The second HIFU exposure series delivered six HIFU
exposures of 2.6 kW cm22 estimated in situ intensity to a
depth of 22 mm beneath the maternal skin, after the fetal
hind limb had spontaneously moved away, and resulted in
vascular occlusion (electronic supplementary material,
table S1). This injury remained evident at post-mortem (day
20) and histological examination suggested a full thickness
skin burn (figure 7d ). There was no evidence of anaemia or
acidosis in this fetus during the follow-up period. There
were no maternal uterine or skin burns, or erythema, in
this animal. The maternal weight was 53 kg. This burn can
be attributed to operator error and inadvertent failure to
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Figure 5. Change in FHRV indices with gestational age. Values represent mean+ s.e.m. in active sleep of short-term variation (STV), standard deviation of normal
to normal intervals (SDNN), normalized LF (nLF) and normalized HF (nHF) power and LF/HF ratio, and in quiet sleep of LF/HF ratio in HIFU-exposed (filled circles;
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9follow the safety constraints used for target selection and
described in the Material and methods section.
4. Discussion
This study demonstrates non-invasive HIFU-mediated pla-
cental vascular occlusion with an efficacy of 100%, with no
detrimental effect on maternal and fetal survival to term.
Mothers and fetuses both made a full recovery from general
anaesthesia, abdominal and fetal surgery, with (n ¼ 6) or
without (n ¼ 6) exposure to HIFU placental vascular
occlusion.
As in our previous study of the acute effects of general
anaesthesia, abdominal and fetal surgery, with or without
exposure to HIFU placental vascular occlusion [5], there
were changes in fetal physiology by the end of the exper-
imental protocol. In this study, following reversal of
anaesthesia in both treatment groups, there was activation
of the fetal sympathetic nervous system, a partially buffered
mixed respiratory and metabolic acidosis, and a lowering offetal oxyhaemoglobin saturation, but not of partial pressure
of arterial oxygen.
Fetal sympathetic activation can be inferred from the
increase in fetal peripheral vascular resistance [20] and fetal
haemoconcentration [21] during the first 48 h following rever-
sal of anaesthesia. Sympathetic stimulation of the splenic
circulation and venous reservoirs decreases venous capaci-
tance and acutely increases the red blood cell count within
the circulation in the fetus [21], presenting as an increase in
haemoglobin concentration and haematocrit, as seen in this
study. Activation of the fetal sympathetic nervous system is
further supported by the finding of an increase in the indices
of fetal heart rate variability (FHRV) for the first 72 h follow-
ing reversal of anaesthesia, attributable, in our results, to an
increase in normalized LF rather than HF power. The fetal
heart rate is known to be influenced by the sympathetic
and parasympathetic nervous systems, both of which
contribute to overall FHRV. Power spectral analysis of the
fetal heart rate on a beat-to-beat basis allows assessment
of the separate contributions of the sympathetic and
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10parasympathetic nervous systems to overall FHRV. nLF
power provides the contribution of the sympathetic nervous
system and nHF power provides the equivalent information
of the parasympathetic nervous system contribution [22,23].
In this study, there was an elevation in nLF power in both
treatment groups which persisted for 72 h following the
reversal in anaesthesia, which resulted in an increase in the
indices of overall FHRV, STV and SDNN. There was no
corresponding increase in nHF power.
It should be noted that this increased fetal sympathetic
outflow appears to be the result of the surgical and exper-
imental procedures described, but not of an intrauterine
hypoxic insult, since the partial pressure of arterial oxygen
remained within normal parameters at all times. This is sup-
ported by the mild increase in femoral arterial vascular
resistance, which was, at its peak, only approximately 50%
above baseline. In comparison, acute hypoxic insults which
significantly lower fetal oxygenation have been reported to
increase fetal femoral arterial resistance by between 300 and
400% [20]. Further, the sympathetically mediated haemocon-
centration will contribute to the maintenance of oxygen
delivery to the fetal tissues. Finally, increased FHRV in
acute hypoxia has been shown to result from the activation
of the parasympathetic rather than the sympathetic nervous
system, and parasympathetic activation was not seen in our
fetuses.
The fall in fetal pH can be attributed to both the accumu-
lation of arterial carbon dioxide in the maternal and
consequently the fetal circulations and to the accumulation
of lactate in the fetal tissues. These are recognized effects of iso-
flurane general anaesthesia regardless of concomitant surgical
or experimental procedures, which would not be required in
any potential human treatment [24,25]. The redistribution of
blood away from peripheral circulation results in anaerobic
metabolism of glucose in peripheral tissues, further lowering
fetal pH and thereby facilitating increased unloading ofoxygen from haemoglobin to fetal tissues [26,27]. While the
degree of acidosis in the fetus in both HIFU-exposed and con-
trol groups was comparable, there were differences observed
in ABE and bicarbonate concentrations. In the HIFU-exposed
group, the ABE was negative, and the bicarbonate concen-
trations were normal; in the control group, the ABE and
bicarbonate were elevated. This suggests that the effect of res-
piratory acidosis was predominant in control animals,
compared to HIFU-exposed animals, where metabolic acido-
sis was more apparent. This may have been related to
the difference in maternal anaesthesia—ewes exposed to
HIFU underwent periods of hyperventilation around HIFU
exposures that were not replicated in control animals. How-
ever, despite these appropriate fetal metabolic compensatory
responses to the surgical and experimental procedures experi-
enced, physiological levels of oxygen and glucose were
available at all points of the post-operative recovery and
follow-up periods [28].
The recovery period for the fetal mixed acidosis, haemo-
concentration and peripheral vasoconstriction was less than
48 h, with no difference between HIFU-exposed and control
groups. Thereafter, fetal values remained within normal
ranges corrected for gestational age [11,28,29]. Similarly, nor-
malized LF power had returned to baseline levels within
72 h, as had the indices of overall FHRV. During the
follow-up period, treatment had no effect on any measure
of FHRV, in either quiet or active sleep states. Furthermore,
the observation of expected ontogenic changes in fetal heart
rate, blood pressure and arterial flows [11,30,31] is suggestive
of the normal ongoing development of the fetal cardiovascu-
lar and endocrine system during this recovery period. This is
supported by plasma cortisol levels, measured on 5 and 20
post-operative days, which showed increases with advancing
gestational age but no difference between treatment groups.
At 121+2 days gestational age (post-operative day 5), fetal
plasma cortisol levels should be around 10 ng ml21, as in
our animals, as the cortisol surge that matures fetal tissues
and triggers parturition in sheep has yet to occur. After a
further 15 days follow-up, fetal plasma cortisol levels were
higher, as expected in the preparation for delivery, but not
different between treatment groups [32]. This rise in
endogenous cortisol levels approaching term underlies the
increase in arterial blood pressure and arterial blood flow
in sheep fetuses as the autonomic nervous system matures
and begins to establish a resting tone [33,34]. Finally,
normal fetal development is further supported by the com-
parable birth weights and body mass indices, without
evidence of asymmetric growth, as previously reported [10].
As only singleton fetuses were used, these results are free
of the potential confounding factors found in multiple
pregnancies.
The HIFU protocol used in this study resulted in a high
occlusion rate of placental vasculature, through intact
maternal skin, despite a reduction in estimated in situ inten-
sity delivered to the target tissue compared to our previous
transdermal experience: from 2.9 (IQR 0.6) kW cm22 [10] to
2.6 (IQR 0.4) kW cm22. This change, together with cooling
and continuous degassing of fluid in the water bag, was suf-
ficient to reduce the rate of skin burns to zero compared to
11% (4/36) [10] in our previous transdermal study. The
mean target depth was 24 mm, which is comparable to the
distance which an anterior placenta lies beneath the abdomi-
nal skin in human pregnancy, meaning that the HIFU system
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Figure 7. Maternal and fetal iatrogenic injury. (a) The photograph shows the maternal abdomen after shaving and depilation and exposure to six HIFU series. The
circled areas are areas of skin redness, which appear to be erythema. (b) The photograph shows a serosal layer uterine burn immediately following HIFU exposures
(noted at subsequent laparotomy-specific HIFU exposure series unknown). The inset shows a close-up of the affected area. (c) The photograph shows the same
uterine burn after 21 days, demonstrating healing without rupture; the inset shows a close-up of the damage. (d ) The photograph shows a skin burn on the anterior
aspect of the left fetal hindlimb. This resulted from five HIFU exposures of estimated in situ ISPTA 2.4 kW cm
22. (Online version in colour.)
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12used here is a clinically relevant one in terms of frequency
used, lesion size and focal length.
The study protocol also demonstrated the ability to ident-
ify, target and use HIFU to occlude six placental vessels within
1 h. Recent work describing updates to fetoscopic laser
procedures describes that a mean of 4 AVAs (range 1–11)
need to be occluded in human treatment [35]. The use of a
mechanical gantry to control the HIFU transducer means
that the HIFU system can either be used for selective coagu-
lation of AVAs or to emulate the Solomon technique, ablating
soft tissue between anastomoses, although this has yet to be
shown to reduce perinatal mortality or severe neonatal mor-
bidity [36]. Both these features show the clinical relevance of
the HIFU protocol and system used here. As both the identi-
fication of AVAs [37] and the vascular equator of the placenta
[38] using ultrasound have been described, this would not be
expected to become a barrier to translation.
Similarly, the pregnant sheep model is a good anatomical
model of the anastomoses within the human monochorionic
placenta, which does not alter with the gestational age of the
sheep pregnancy, and was the first model in which fetoscopic
laser was tested [39]. The sheep placental mass is divided into
70–80 areas of enmeshed maternal and fetal tissue and villi,
called placentomes, where haemotrophic exchange takes
place. Fetal vessels emerge from placentomes and run
between placentomes in the allantoic membranes and can
therefore be targeted within placental tissue as they would
need to be in a monochorionic placenta. In monochorionic
placentae, arterio-venous anastomoses are reported to be
0.3–2.1 mm in diameter [40,41]. The vessels occluded in our
study had a mean diameter of 1.4 mm, with a maximum
diameter of up to 4.1 mm, demonstrating the capability of
the HIFU system used to occlude vessels of a clinically
relevant size.The most significant injury encountered in this study
was a burn to a fetal hind limb. As detailed in the Results
section, this resulted from both mistargeting, and the fetal
hind limb moving closer to the target between mapping
and delivery of HIFU, without being noted. While undesir-
able, this event illustrates several points. Firstly, it shows the
importance of continuously identifying the fetal position
relative to the HIFU focal zone, using real-time imaging
techniques. Secondly, it emphasizes the importance of build-
ing in to the HIFU protocol systematic safety checks to
reduce the risk of unwanted effects that can reasonably be
anticipated. Thirdly, it is reassuring that this fetus recovered
without evidence of compromise, despite the burn. This is
an important finding when considering translation into
human therapy.
Additionally, there was a single uterine serosal burn, the
cause of which was not established. There was nothing unu-
sual about the target vessels in terms of size, type or
placement of vessel which could explain the burn. While
the maternal weight—55 kg—was at the upper end of the
range of weights recorded, three other ewes with weights
53–55 kg did not sustain uterine burns. Regardless of the
cause, this injury did not lead to uterine rupture or other
obstetric complications.
In conclusion, maternal and fetal recovery from HIFU-
mediated placental vascular occlusion, followed by normal
long-term normal physiology is possible. We observed no
evidence of fetal death, compromise or stress, while demon-
strating normal maturation and development the fetal
cardiovascular and autonomic nervous systems. This study
also demonstrated that such positive results can be achieved
in the presence of uterine and fetal burns. Combined with the
high success rate of selective placental vascular occlusion,
HIFU has potential as an in utero therapy in relevant
royalsocietypublishing.org/journal/rsif
13human pregnancy conditions, such as TTTS where highly
invasive therapy is otherwise currently the only option.
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